Inmed Pharmaceuticals Inc. 8-K Report: Key Updates & NASDAQ Insights

Based on the provided section of the financial report, here are the key insights extracted:

Company Information:

• Name: Inmed Pharmaceuticals Inc.
• CIK Number: 0001728328
• SEC File Number: 001-39685
• Tax ID: 98-1428279
• Address: Suite 1445 - 885 W. Georgia Street, Vancouver, CA V6C 3E8
• Phone Number: 604-669-7207
• Stock Exchange: NASDAQ
• Ticker Symbol: INM

Report Details:

• Report Type: 8-K (a report filed to announce major events that shareholders should know about)
• Date of Report: February 12, 2025
• Period of Reporting: The report is effective as of February 12, 2025.

Financial Metrics:

• Common Shares: The company has common shares with no par value.
• Reporting Unit: Financials are presented in USD (United States Dollars) and shares.

Additional Notes:

• The report is structured in XBRL (eXtensible Business Reporting Language), which is commonly used for SEC filings, suggesting a focus on providing detailed and structured financial data.
• There are no specific financial figures or metrics included in the segment provided, indicating that this is likely a header or introductory section of a more detailed report.

Summary:

Inmed Pharmaceuticals Inc. filed an 8-K report on February 12, 2025, announcing key company information and confirming its status on NASDAQ under the ticker INM. More detailed financial data would likely be present in subsequent sections of the report.